Mahathir Bayena

BNY (NYSE:BNY) reported fourth-quarter 2025 results that surpassed Wall Street’s expectations, fueled by a surge in fee-based income and a record expansion of its custody empire.

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo have announced the first patient has been dosed in the TROPION-Lung17 Phase 3 trial, a landmark study that marks the first time an antibody-drug conjugate (ADC) is being evaluated using a prospective, AI-powered biomarker in lung cancer.

Treace Medical Concepts (NASDAQ:TMCI) shares are under scrutiny after the bunion-correction specialist reported preliminary fourth-quarter revenue that reflected a nearly double-digit decline.

Black Rifle Coffee Company (NYSE:BRCC) confirmed today that it expects to meet its previously issued financial targets for the 2025 fiscal year, despite a minor gross margin compression caused by a product formulation change.

AbbVie (NYSE:ABBV) has entered into a voluntary three-year agreement with the Trump administration, pledging a massive $100 billion investment in U.S.-based research, development, and manufacturing over the next decade.

Bitwise has pushed back against criticism of Bitcoin in US retirement plans as regulators face renewed scrutiny.

Jack Smith is scheduled to appear in a public congressional hearing next week over his investigations into Donald Trump.

Eric Adams has unveiled plans for a new NYC Token aimed at funding education and promoting blockchain awareness.

The UK military chief has warned that Britain is not yet ready for the demands of a potential full-scale conflict.

SEC chair Paul Atkins says it’s uncertain whether the United States would take action on Venezuela’s reported Bitcoin holdings.